Related Experiment Video
Updated: Sep 9, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Frailty and [177Lu]Lu-PSMA-617 therapy: tools and strategies for older men with metastatic castration-resistant
Matteo Bauckneht1,2, Nicolò Borsellino3, Giuseppe Ferdinando Colloca4
1Department of Health Sciences (DISSAL), University of Genova, Genova, Italy.
Abstract:
The prognosis of metastatic castration-resistant prostate cancer is dismal. [177Lu]Lutetium-prostate-specific membrane antigen (PSMA)-617 ([177Lu]Lu-PSMA-617) is the new standard of care for PSMA-positive mCRPC previously treated with ARPI and taxane-based chemotherapy. The efficacy and safety of [177Lu]Lu-PSMA-617 have been confirmed by phase 2 (TheraP [NCT03392428]) and phase 3 (VISION study [NCT02511664] and PSMAfore trial [NCT04689828]) clinical trials. A substantial proportion of patients with mCRPC are older adults; however, chronological age alone should not be considered a contraindication to [177Lu]Lu-PSMA-617 therapy. Instead, therapeutic decisions must be guided by a comprehensive evaluation of life expectancy, comorbidities, and frailty. Here we review the effectiveness and safety data for [177Lu]Lu-PSMA-617, present tools for the geriatric and frailty assessments in clinical practice and discuss its utility and therapeutic indications in patients with different types of frailty.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers

